BLTE News - Candlesense

Belite Bio to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal disea...

Investor

11 days ago

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal disea...

What are the potential risks highlighted in the release (e.g., regulatory, clinical trial timelines, financing) that traders should monitor? Is there any insight into the competitive landscape for retinal disease therapeutics that could affect Belite Bio's market share potential? How might the recent results impact short‑term stock price volatility and trading volume?

Earnings

27 days ago

Belite Bio Announces Registered Direct Offering of $15 Million

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting ...

What are the potential risks if the company fails to achieve the projected milestones, given the increased capital base? How does this capital raise improve the odds of reaching key clinical milestones and potentially catalyze a stock price rally? What is the anticipated dilution for the five‑year warrants based on historical exercise rates for similar biotech offers?

Funding

about 1 month ago